Published: 3. March, 2022
Cessatech A/S publishes its annual report for the fiscal year 2021. “We managed to…
Cessatech A/S publishes its annual report for the fiscal year 2021.
“We managed to complete most of the tasks we had set up for the year 2021 – including finalizing the IMP from our manufacturer, reporting on the Registry Study and initiating the important Phase 2 trials (0204 and 0206) and obtaining the first US patent for CT001. I am very proud that we managed it all together with exercise of the warrant TO 1 with app 97% success rate – and we have many activities to be completed in 2022, but especially the results of clinical studies, will be instrumental for our future success!”
CEO – Jes Trygved